Drugs / CD388
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07300085 | Nov 2025 → Dec 2026 expected | — | Cidara Therapeutics Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05619536 | Oct 2022 → Jul 2023 | — | Cidara Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05285137 | Mar 2022 → Oct 2023 | — | Cidara Therapeutics Inc. | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT07225959 | Oct 2025 → Jul 2027 expected | — | Cidara Therapeutics Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06609460 | Sep 2024 → Oct 2025 | influenza | Cidara Therapeutics Inc. | Completed | Met primary |
| Phase 2 | NCT05523089 | Sep 2022 → Jul 2023 | influenza | Cidara Therapeutics Inc. | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT07159763 | Sep 2025 → Jun 2027 expected | influenza | Cidara Therapeutics Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD388 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06609460 ↗ |
| Known as | MK-1406 | “CD388 (also known as MK-1406)” NCT07159763 ↗ |
| Modality | Other / unclassified | “a Novel Long-acting Antiviral Conjugate” NCT06609460 ↗ |
| Route | Intramuscular | “administered by IM injection” NCT05285137 ↗ |